Pfizer is on a diet, and it shows. The company pumped up 2013 earnings despite a sizable slide in sales, thanks to layoffs and cost cuts, not to mention the successful spinoff of its animal health business, Zoetis. And it's looking for more of the same for 2014.
It's well-documented that antibiotic resistance is a growing public health threat. Drug-resistant bacteria infect about 2 million Americans a year, causing at least 23,000 deaths, according to CDC data. Now, to keep resistance from mounting, the FDA is rolling out a plan to cut down on antibiotics use in livestock, enlisting the drugs' producers--companies like Eli Lilly and Zoetis--to help them do it.
Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer?
Pfizer is doing some reorganization--the company said Monday that it would split its operations into three distinct units, two focused on "innovative" drugs and a third including so-called "value" business.
Pfizer has been hit hard by patent losses and some of its new drugs are not performing as well as it would like, but something CEO Ian Read is really strong at is buying back shares, and so he says the company will do it again.
Pfizer is cutting the apron strings at Zoetis. Just months after its highly successful IPO, in which Pfizer sold off a 20% stake, the animal health business is set to become fully independent. Pfizer is offering a stock swap to its shareholders, who can exchange $100 in Pfizer shares for roughly $107 worth of Zoetis stock.
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
Stock for Pfizer's animal health spinoff Zoetis soared 21% after raising more than $2.2 billion in its initial public offering.
The spinoff of Pfizer's animal health unit has gone off with such success that it may make some wonder why CEO Ian Read didn't keep it and dump the challenging pharmaceutical business.
Pfizer's animal health group Zoetis goes public today, with an IPO valued at up to $2.2 billion.